These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17318304)

  • 21. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
    Alvarez XA; Sampedro C; Pérez P; Laredo M; Couceiro V; Hernández A; Figueroa J; Varela M; Arias D; Corzo L; Zas R; Lombardi V; Fernández-Novoa L; Pichel V; Cacabelos R; Windisch M; Aleixandre M; Moessler H
    Int Clin Psychopharmacol; 2003 Sep; 18(5):271-8. PubMed ID: 12920387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).
    Rüther E; Ritter R; Apecechea M; Freytag S; Windisch M
    Pharmacopsychiatry; 1994 Jan; 27(1):32-40. PubMed ID: 8159781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.
    Bornstein NM; Guekht A; Vester J; Heiss WD; Gusev E; Hömberg V; Rahlfs VW; Bajenaru O; Popescu BO; Muresanu D
    Neurol Sci; 2018 Apr; 39(4):629-640. PubMed ID: 29248999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Jiang D; Yang X; Li M; Wang Y; Wang Y
    J Neural Transm (Vienna); 2015 Aug; 122(8):1157-66. PubMed ID: 25547862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
    Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
    Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.
    Alvarez XA; Sampedro C; Cacabelos R; Linares C; Aleixandre M; García-Fantini M; Moessler H
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):867-72. PubMed ID: 19531281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cerebrolysin in treatment of painful diabetic neuropathy].
    Biesenbach G; Grafinger P; Eichbauer-Sturm G; Zazgornik J
    Wien Med Wochenschr; 1997; 147(3):63-6. PubMed ID: 9173675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cerebrolysin in neurological and psychiatric practice].
    Vilenskiĭ BS
    Lik Sprava; 1997; (6):139-42. PubMed ID: 9589960
    [No Abstract]   [Full Text] [Related]  

  • 34. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist.
    Flint AJ; van Reekum R
    Can J Psychiatry; 1998 Sep; 43(7):689-97. PubMed ID: 9773218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease.
    Gauthier S; Lopez OL; Waldemar G; Jones RW; Cummings J; Zhang R; Schindler R; Schwam E
    Int Psychogeriatr; 2010 Sep; 22(6):973-83. PubMed ID: 20534179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
    Lang W; Stadler CH; Poljakovic Z; Fleet D;
    Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Zhang D; Dong Y; Li Y; Chen J; Wang J; Hou L
    Biomed Res Int; 2017; 2017():4191670. PubMed ID: 28656143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.